We evaluated the company’s patents, clinical data, and unique formulations. Our team conducted an analysis of potential market size, regulatory pathways, and revenue from orphan drug designation to arrive at a fair valuation.

Client Outcome

The valuation facilitated licensing agreements with established pharmaceutical companies, allowing the firm to increase its R&D funding and accelerate drug development for rare disease treatments.